Biosplice Therapeutics has initiated dosing in an investigator-initiated Phase 1 study testing cirtuvivint, a pan-CLK/DYRK inhibitor, in combination with olaparib in women with BRCA-mutated and/or HRD platinum-resistant ovarian cancer who have previously received a PARP inhibitor. The open-label trial at UCHealth University of Colorado Hospital features a dose-escalation phase followed by expansion, with primary goals to establish safety, tolerability, and a recommended Phase 2 dose.
The move advances a resistance-reversal strategy rooted in preclinical evidence that cirtuvivint suppresses WNT/TCF signaling and modulates oncogenic splicing programs that tumor cells exploit to evade PARP inhibition. In PARP-resistant high-grade serous ovarian cancer models, cirtuvivint combined with olaparib slowed tumor progression and extended survival, with signals of immune microenvironment remodeling. The clinical design centers on patients with documented prior PARP exposure, positioning the study to interrogate re-sensitization rather than first-line potentiation.
Strategically, this is a targeted bet on mechanism over brute-force combination therapy. Rather than layering additional cytotoxics, Biosplice is leaning into pathway cross-talk and splicing control to shut down adaptive escape routes. An investigator-initiated construct limits sponsor burn while generating early clinical signal in a hard-to-treat niche where single-agent PARP options post-resistance have minimal activity. It also situates Biosplice within a competitive field investigating PARP resistance combinations, including ATR, WEE1, and DNA damage response agents, but with a differentiated angle through CLK/DYRK inhibition and WNT suppression.
For sites, the eligibility stack—platinum resistance, BRCA/HRD status, and prior PARPi—narrows the funnel and raises operational overhead for molecular verification and documentation of prior therapy. The all-oral regimen simplifies logistics, yet safety oversight will be intensive: olaparib’s hematologic toxicity profile overlaps with the cytopenias common in this population, and early-phase dose finding will need careful coordination of labs, dose holds, and drug–drug interaction checks. Sites with embedded molecular diagnostics and gynecologic oncology volume will have an enrollment advantage, while community settings may struggle without streamlined HRD testing workflows.
Sponsors and CROs should note the signal strategy: biomarker-led enrollment, translational endpoints, and a focus on pharmacodynamic readouts such as WNT/β-catenin activity and splicing signatures. If the combination shows tolerability and disease control, the likely next step is a company-sponsored expansion with stratification by BRCA versus non-BRCA HRD and clearer definitions of PARP resistance. Regulators have become more exacting around post-PARPi settings; durability, consistency across resistance mechanisms, and a coherent mechanistic package will matter as much as response rates. Companion diagnostics alignment—whether central HRD testing or predefined genomic assays—will influence both study scalability and regulatory dialogue.
What to watch next are the dose-limiting toxicities and recommended Phase 2 dose, along with early signs of re-sensitization in previously PARP-exposed patients. The bar is modest on efficacy but high on safety and biological plausibility. A clean safety profile and credible pharmacodynamic evidence could catalyze a faster pivot to multicenter expansion and partnerships. Conversely, overlapping myelosuppression or inconclusive biomarker data would stall momentum in a space where multiple DDR-based combinations are already competing for the same patient subset. The broader question is whether splicing modulation and WNT pathway control can translate from preclinical promise to clinically meaningful resistance reversal—an answer that will shape not only this program but the next wave of PARP-combination design.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
